Larimar Therapeutics

OverviewSuggest Edit

Larimar Therapeutics (formerly known as Zafgen) is a biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity and complex metabolic disorders. The company is focused on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. Larimar Therapeutics has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. The Company's lead product candidate is ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of metabolic diseases including type 2 diabetes and obesity.

Larimar Therapeutics is conducting a Phase 1 clinical trial of ZGN-1061 in the Netherlands, and have completed dosing patients in the single ascending dose, or SAD, portion and are currently dosing patients in the multiple ascending dose, or MAD, portion. This clinical trial is evaluating ZGN-1061 for safety, tolerability, and pharmacokinetics while also gaining an early indication of weight loss efficacy over four weeks of treatment.

TypePublic
Founded2005
HQBala Cynwyd, PA, US
Websitelarimartx.com

Latest Updates

Employees (est.) (Mar 2020)7(-81%)
Job Openings3
Revenue (FY, 2019)$0
Share Price (Jan 2022)$8.9
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Larimar Therapeutics

Carole Ben-Maimon

Carole Ben-Maimon

President and Chief Executive Officer
Michael Celano

Michael Celano

Chief Financial Officer
Nancy M. Ruiz

Nancy M. Ruiz

Chief Medical Officer
John Berman

John Berman

Vice President of Finance and Operations
Jennifer Johansson

Jennifer Johansson

Vice President of Regulatory Affairs and Counsel
David Bettoun

David Bettoun

Vice President of Discovery and Non-Clinical R&D
Show more

Larimar Therapeutics Office Locations

Larimar Therapeutics has an office in Bala Cynwyd
Bala Cynwyd, PA, US (HQ)
Bala Plaza
Show all (1)

Larimar Therapeutics Financials and Metrics

Larimar Therapeutics Revenue

USD

Net income (FY, 2020)

(42.5m)

EBIT (FY, 2020)

(42.8m)

Market capitalization (24-Jan-2022)

152.5m

Closing stock price (24-Jan-2022)

8.9

Cash (31-Dec-2020)

68.1m

EV

90.9m
Larimar Therapeutics's current market capitalization is $152.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

8.1m19.2m18.3m12.2m13.2m16.2m11.4m

R&D expense

27.4m54.6m39.9m40.8m47.9m23.9m31.4m

Operating expense total

35.5m73.8m58.2m53.0m61.1m40.1m42.8m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

1.3m2.3m3.0m5.1m5.5m5.4m4.9m4.8m3.6m3.0m3.1m3.3m3.4m3.3m3.6m3.6m3.6m3.6m2.5m

R&D expense

4.7m12.1m10.2m12.5m14.2m12.5m10.2m10.0m9.7m10.5m9.7m12.4m12.2m11.8m9.6m8.6m5.3m8.9m

Operating expense total

6.0m14.4m13.2m17.6m19.7m17.9m15.1m14.8m13.3m13.5m12.8m15.7m15.6m15.2m13.3m12.2m8.9m3.6m11.4m
USDQ2, 2014

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.1 x
Show all financial metrics

Larimar Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Larimar Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Larimar Therapeutics Online and Social Media Presence

Embed Graph

Larimar Therapeutics News and Updates

Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at…

Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the Gug…

Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results

BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financial…

Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020- Company signed $80 million in private placement financing with biotechnology focused institutional investors- New Board Chair, Chief Medical Officer and Chief Financial Officer appointed

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

Zafgen Reports Second Quarter 2019 Operating and Financial Results

Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins
Show more

Larimar Therapeutics Blogs

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

- Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich’s ataxia (FA) - Subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in buccal cells of FA patients that were at or in excess of

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

- Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021 - Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa.

Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference Content Import Thu, 09/10/2020 - 08:01 Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference September 10, 2020 at 8:00 AM …

Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference

Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Content Import Tue, 08/04/2020 - 08:02 Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference August 4, 2020 at 8:00 AM EDT This release is a backfill …

Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia

Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia Content Import Tue, 07/28/2020 - 08:01 Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Rec…

Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia

BALA CYNWYD, Pa. , July 20, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that patients have been dosed in the third cohort of a Phase 1 clinical trial to evaluate
Show more

Larimar Therapeutics Frequently Asked Questions

  • When was Larimar Therapeutics founded?

    Larimar Therapeutics was founded in 2005.

  • Who are Larimar Therapeutics key executives?

    Larimar Therapeutics's key executives are Carole Ben-Maimon, Michael Celano and Nancy M. Ruiz.

  • How many employees does Larimar Therapeutics have?

    Larimar Therapeutics has 7 employees.

  • Who are Larimar Therapeutics competitors?

    Competitors of Larimar Therapeutics include Lobesity, BIOTON and Gan & Lee Pharmaceuticals.

  • Where is Larimar Therapeutics headquarters?

    Larimar Therapeutics headquarters is located at Bala Plaza, Bala Cynwyd.

  • Where are Larimar Therapeutics offices?

    Larimar Therapeutics has an office in Bala Cynwyd.

  • How many offices does Larimar Therapeutics have?

    Larimar Therapeutics has 1 office.